

HSA approves TCR immunotherapy trial for liver cancer

20 August 2018 | News

This is the first such trial in Singapore and for the region that uses precision T cell receptor (TCR) immune cell therapy to target Hepatitis B virus (HBV)-related liver cancer.



Lion TCR Pte. Ltd., a Singapore-based Biotech company has received approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multi-centre clinical study of its product candidate (LioCyx) for treatment of relapsed liver cancer post-liver transplantation.

This is the first such trial in Singapore and for the region that uses precision T cell receptor (TCR) immune cell therapy to target Hepatitis B virus (HBV)-related liver cancer, which forms at least 80% of liver cancers in Asia.

LioCyx is developed by Lion TCR's scientific founder, Prof. Antonio Bertoletti, a world-renowned HBV-liver cancer clinician scientist. Several Investigator-sponsored trials of LioCyx in Singapore and China have showed results of good safety profile and encouraging signs of efficacy.

"We are very delighted with the approval of Phase I/II clinical trial of our LioCyx, the first engineered TCR-T cell therapy for treatment of liver cancer in Singapore. It is an utmost encouragement on the recognition of innovative therapy for patients in need. Singapore HSA has been very efficient, transparent and professional in reviewing our application for the clinical trial of this innovative immunotherapy", said Dr. Victor Li Lietao, founder and CEO of Lion TCR.